(RLMD) Relmada Therapeutics - Overview
Stock: Gemcitabine, Docetaxel, Sepranolone, Psilocybin
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 128% |
| Relative Tail Risk | -23.8% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 2.27 |
| Alpha | 907.01 |
| Character TTM | |
|---|---|
| Beta | 0.861 |
| Beta Downside | 0.428 |
| Drawdowns 3y | |
|---|---|
| Max DD | 96.30% |
| CAGR/Max DD | 0.01 |
Description: RLMD Relmada Therapeutics December 23, 2025
Relmada Therapeutics, Inc. (NASDAQ:RLMD) is a U.S. clinical-stage biotech focused on specialty drug delivery platforms, headquartered in Coral Gables, Florida, and operating under the GICS Pharmaceuticals sub-industry.
The company’s lead asset, NDV-01, is a controlled-release intravesical formulation that combines gemcitabine and docetaxel for aggressive non-muscle invasive bladder cancer (NMIBC). It is currently in a Phase 2 trial; NMIBC represents roughly a $2 billion U.S. market, and successful intravesical therapy could capture a meaningful share of that niche.
Relmada’s secondary pipeline includes sepranolone, a neurosteroid epimer of allopregnanolone positioned for Phase 2b trials in Prader-Willi Syndrome, Tourette Syndrome, excessive tremor, and other conditions linked to heightened GABAergic activity. Additionally, REL-P11, a modified-release psilocybin formulation, has cleared a Phase 1 safety study for metabolic disease indications.
As of the most recent filing, Relmada reported cash and equivalents of approximately $45 million, providing runway for the next 12-18 months of R&D without additional financing. The biotech sector’s average cash burn for Phase 2 programs hovers around $20-$30 million per year, suggesting Relmada’s liquidity is modest but sufficient to advance its current trials, assuming no major cost overruns.
For a deeper dive into RLMD’s valuation metrics and peer comparison, the ValueRay platform offers a concise, data-driven snapshot.
Piotroski VR‑10 (Strict, 0-10) 0.5
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -2.69 > 0.02 and ΔFCF/TA -173.3 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -2.69 > 3% & CFO -40.0m > Net Income -56.2m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 2.86 > 1.5 & < 3 |
| Outstanding Shares: last quarter (33.2m) vs 12m ago 10.00% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 0.0%; Δ 0.0% > 0%) |
| Interest Coverage Ratio: -2.12 > 6 (EBITDA TTM -57.2m / Interest Expense TTM 18.0m) |
Altman Z'' -15.00
| A: 0.65 (Total Current Assets 14.9m - Total Current Liabilities 5.19m) / Total Assets 14.9m |
| B: -45.60 (Retained Earnings -678.4m / Total Assets 14.9m) |
| C: -1.08 (EBIT TTM -38.2m / Avg Total Assets 35.3m) |
| D: -125.4 (Book Value of Equity -678.4m / Total Liabilities 5.41m) |
| Altman-Z'' Score: -283.3 = D |
What is the price of RLMD shares?
Over the past week, the price has changed by +9.30%, over one month by -4.90%, over three months by +48.66% and over the past year by +1034.50%.
Is RLMD a buy, sell or hold?
- StrongBuy: 0
- Buy: 0
- Hold: 3
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the RLMD price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 5.5 | 41.8% |
| Analysts Target Price | 5.5 | 41.8% |
| ValueRay Target Price | 4.2 | 8.5% |
RLMD Fundamental Data Overview February 03, 2026
Revenue TTM = 0.0 USD
EBIT TTM = -38.2m USD
EBITDA TTM = -57.2m USD
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = unknown
Net Debt = -1.38m USD (from netDebt column, last quarter)
Enterprise Value = 316.8m USD (330.7m + (null Debt) - CCE 13.9m)
Interest Coverage Ratio = -2.12 (Ebit TTM -38.2m / Interest Expense TTM 18.0m)
EV/FCF = -7.92x (Enterprise Value 316.8m / FCF TTM -40.0m)
FCF Yield = -12.62% (FCF TTM -40.0m / Enterprise Value 316.8m)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = 21.30 (Enterprise Value 316.8m / Total Assets 14.9m)
Interest Expense / Debt = unknown (Interest Expense 1.36m / Debt none)
Taxrate = 21.0% (US default 21%)
NOPAT = -30.1m (EBIT -38.2m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 2.86 (Total Current Assets 14.9m / Total Current Liabilities 5.19m)
Debt / Equity = unknown (Debt none)
Debt / EBITDA = 0.02 (negative EBITDA) (Net Debt -1.38m / EBITDA -57.2m)
Debt / FCF = 0.03 (negative FCF - burning cash) (Net Debt -1.38m / FCF TTM -40.0m)
Total Stockholder Equity = 20.8m (last 4 quarters mean from totalStockholderEquity)
RoA = -159.1% (out of range, set to none)
RoE = -269.5% (Net Income TTM -56.2m / Total Stockholder Equity 20.8m)
RoCE = -393.9% (out of range, set to none) (EBIT -38.2m / Capital Employed (Total Assets 14.9m - Current Liab 5.19m))
RoIC = -144.6% (out of range, set to none) (NOPAT -30.1m / Invested Capital 20.8m)
WACC = 9.09% (E(330.7m)/V(330.7m) * Re(9.09%) + (debt-free company))
Discount Rate = 9.09% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 5.01%
Fair Price DCF = unknown (Cash Flow -40.0m)
EPS Correlation: 94.43 | EPS CAGR: 116.0% | SUE: 1.09 | # QB: 2
Revenue Correlation: N/A | Revenue CAGR: 0.0% | SUE: 0.0 | # QB: 0
EPS next Year (2026-12-31): EPS=-0.36 | Chg30d=+0.630 | Revisions Net=+1 | Growth EPS=+56.6% | Growth Revenue=+0.0%